TBC1D16

TBC1D16 is a TBC-domain Rab GTPase-activating protein (GAP) that controls endosomal membrane trafficking by accelerating GTP hydrolysis on Rab4A, thereby restraining recycling of internalized receptors back to the plasma membrane (PMID:23019362). The protein partitions between cytosol and membranes, with its membrane pool localizing to early endosomes (EEA1-positive) together with transferrin receptor and EGFR; catalytically active TBC1D16 reduces transferrin receptor recycling without affecting its internalization, redistributes Rab4A, and promotes EGF-stimulated EGFR degradation with consequent attenuation of EGFR signaling (PMID:23019362). GAP activity depends on the conserved catalytic TBC residues R494 and Q531 (PMID:23019362, PMID:34367131). A short isoform reactivated by promoter hypomethylation (TBC1D16-47KD) additionally engages RAB5C to control EGFR levels and drives melanoma growth and metastasis (PMID:26030178), and TBC1D16 is itself a melanoma proliferation dependency (PMID:21129771). Beyond endosomal trafficking, TBC1D16 acts as an antiviral host factor that suppresses Prototype Foamy Virus replication and enhances IFN-β responses through its Rab5C GAP activity (PMID:34367131), and it suppresses NF-κB signaling in hepatocellular carcinoma (PMID:41677126). Its transcription is governed by a super enhancer in colorectal cancer (PMID:34737287) and by the transcription factor SP1 in hepatocellular carcinoma (PMID:41677126).

1. 2010 Low

   Before any biochemical role was known, an unbiased genomic screen asked which amplified genes drive melanoma proliferation, nominating TBC1D16 as a candidate trafficking regulator.

   Evidence Integrative Bayesian analysis of copy number and expression with empirical knockdown validation in melanoma cells

   PMID:21129771

   Open questions at the time

   • Computational prediction with limited mechanistic resolution; no molecular activity defined
   • Did not establish the GAP function or any Rab substrate
   • Dependency mechanism in melanoma not resolved
2. 2012 High

   To define TBC1D16's molecular activity, this work established it as a Rab4A GAP that regulates receptor recycling and EGFR turnover, converting a trafficking 'candidate' into a defined enzyme.

   Evidence In vitro GTPase assay, R494A catalytic mutant, endosomal colocalization imaging, transferrin recycling and EGFR degradation assays in HeLa cells

   PMID:23019362

   Open questions at the time

   • Full Rab substrate spectrum beyond Rab4A not delineated here
   • Mechanism targeting TBC1D16 to specific endosomal subdomains unknown
   • No structural model of the catalytic interaction
3. 2015 Medium

   Building on the GAP function, this study asked how TBC1D16 promotes cancer and identified a hypomethylation-reactivated short isoform that targets RAB5C to control EGFR in melanoma.

   Evidence Immunoprecipitation/mass spectrometry to identify RAB5C, DNA methylation analysis, and in vivo melanoma growth/metastasis assays

   PMID:26030178

   Open questions at the time

   • Direct in vitro GAP activity toward RAB5C not biochemically reconstituted here
   • Relationship between Rab4A and RAB5C targeting by different isoforms unclear
   • Single lab
4. 2021 Medium

   Extending TBC1D16 beyond cancer trafficking, this work showed its Rab5C GAP activity functions as an antiviral effector against Prototype Foamy Virus and boosts interferon responses.

   Evidence Overexpression/siRNA, R494 and Q531 active-site mutants, viral replication assays, IFN-β reporter assays

   PMID:34367131

   Open questions at the time

   • Mechanistic link between Rab5C GAP activity and viral transcription suppression not detailed
   • How TBC1D16 enhances IFN-β production unresolved
   • Single lab
5. 2021 Medium

   To explain TBC1D16 overexpression in tumors, this study identified a super enhancer driving its transcription in colorectal cancer and tumorigenesis.

   Evidence H3K27ac ChIP-Seq super enhancer profiling across 73 colorectal cancer patient tissue pairs plus functional validation

   PMID:34737287

   Open questions at the time

   • Downstream trafficking/GAP consequences in colorectal cancer not linked to phenotype
   • Transcription factors binding the super enhancer not identified
   • Single lab
6. 2026 Medium

   This work connected TBC1D16 to a distinct signaling axis, showing it suppresses NF-κB signaling in hepatocellular carcinoma and is transcriptionally driven by SP1.

   Evidence siRNA knockdown with proliferation/migration/invasion assays, RNA-seq pathway analysis, NF-κB validation, transcription factor analysis

   PMID:41677126

   Open questions at the time

   • Mechanism linking Rab GAP activity to NF-κB regulation not defined
   • Direct SP1 binding to the TBC1D16 promoter not biochemically confirmed
   • Single lab

• It remains unresolved how a single Rab GAP integrates endosomal receptor trafficking with antiviral interferon signaling and NF-κB suppression, and whether these arise from shared or distinct Rab substrates and isoforms.
• No structural model of TBC1D16 substrate engagement
• Functional division of labor between full-length and 47KD isoforms across contexts unclear
• Mechanism coupling Rab GAP activity to NF-κB and interferon outputs unknown